Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia
| Status: | Completed |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 1/3/2018 |
| Start Date: | July 2011 |
| End Date: | April 2013 |
Remifentanil IV PCA for Ablation of Idiopathic Ventricular Tachycardia
Determine effects of remifentanil conscious sedation in patients undergoing
Electrophysiological (EP) studies for the ablation of idiopathic ventricular tachycardia
and/or persistent frequent premature ventricular contractions (PVCs) of non-ischemic origin
Electrophysiological (EP) studies for the ablation of idiopathic ventricular tachycardia
and/or persistent frequent premature ventricular contractions (PVCs) of non-ischemic origin
The purpose of the study is to determine the effects of remifentanil conscious sedation in
patients undergoing Electrophysiological (EP) studies for the ablation of idiopathic
ventricular tachycardia and/or persistent frequent PVCs of non-ischemic origin.
Remifentanil is an analgesic- synthetic opiate with an very short half life. It is rapidly
broken down by enzymes in the blood and is ideally suited for continuous sedation. The effect
is practically eliminated within 5 minutes after the intravenous sedation is stopped.
You are being asked to participate in this study because you are already scheduled to undergo
EP studies under the care of your cardiologist for the ablation of idiopathic ventricular
tachycardia and/or persistent frequent PVCs of non-ischemic origin.
patients undergoing Electrophysiological (EP) studies for the ablation of idiopathic
ventricular tachycardia and/or persistent frequent PVCs of non-ischemic origin.
Remifentanil is an analgesic- synthetic opiate with an very short half life. It is rapidly
broken down by enzymes in the blood and is ideally suited for continuous sedation. The effect
is practically eliminated within 5 minutes after the intravenous sedation is stopped.
You are being asked to participate in this study because you are already scheduled to undergo
EP studies under the care of your cardiologist for the ablation of idiopathic ventricular
tachycardia and/or persistent frequent PVCs of non-ischemic origin.
Inclusion Criteria:
- Patients scheduled to undergo EP studies for the ablation of idiopathic ventricular
tachycardia and/or persistent frequent PVCs of non-ischemic origin
- Patients between 18 and 65
- ASA 1-3
Exclusion Criteria:
- ASA 4 and 5
- Age 18 and 65
We found this trial at
1
site
Click here to add this to my saved trials
